Institute of Transport and Logistics Studies.  Faculty of Economics and Business. The University of Sydne

A Anokhin

A Menke

A Parmeggiani

A Yasuhara

AF Leuchter

AJ Capute

AJ Rush

AR Clarke

C Debattista

C Hamani

C Mulert

C Sander

CC Kuo

CE Beijsterveldt van

CE Tenke

CH Johnson

CL Ehlers

D Ebert

D Posthuma

D Spronk

DA Pizzagalli

DF Hermens

DJ Smit

DV Iosifescu

DW Beebe

E Davids

E Niedermeyer

ED Adrian

ES Lander

F Ducci

F Lemere

F Vogel

G Belenky

G Fallone

G Hefner

G Miller

G Ulrich

G Winterer

GE Bruder

GE Simon

GS Smith

H Asada

H Frieling

HF Zoon

HH Jasper

HP Dongen Van

HS Mayberg

I Iglowstein

IA Cook

II Gottesman

J Axelsson

J Dollman

J Schwartz

J Volavka

J Wu

JB Savitz

JC Wu

JE Goodwin

JG Small

JG Wood

JH Satterfield

JM Gatt

JM Swanson

JR Hughes

KB Heijden van der

L Matricciani

LJ Bierut

M Adamaszek

M Arns

M Bares

M Candy

M Fink

English

Item does not contain fulltextThis chapter summarises recent developments on personalised medicine in psychiatry with a focus on ADHD and depression and their associated biomarkers and phenotypes. Several neurophysiological subtypes in ADHD and depression and their relation to treatment outcome are reviewed. The first important subgroup consists of the 'impaired vigilance' subgroup with often-reported excess frontal theta or alpha activity. This EEG subtype explains ADHD symptoms well based on the EEG Vigilance model, and these ADHD patients responds well to stimulant medication. In depression this subtype might be unresponsive to antidepressant treatments, and some studies suggest these depressive patients might respond better to stimulant medication. Further research should investigate whether sleep problems underlie this impaired vigilance subgroup, thereby perhaps providing a route to more specific treatments for this subgroup. Finally, a slow individual alpha peak frequency is an endophenotype associated with treatment resistance in ADHD and depression. Future studies should incorporate this endophenotype in clinical trials to investigate further the efficacy of new treatments in this substantial subgroup of patients

Arns, M.W.

Olbrich, S.

Radboud Repository

Personalized Medicine in ADHD and Depression: Use of Pharmaco-EEG

Martijn Arns

Sebastian Olbrich

Crossref

This chapter summarises recent developments on personalised medicine in psychiatry with a focus on ADHD and depression and their associated biomarkers and phenotypes. Several neurophysiological subtypes in ADHD and depression and their relation to treatment outcome are reviewed. The first important subgroup consists of the ‘impaired vigilance’ subgroup with oftenreported excess frontal theta or alpha activity. This EEG subtype explains ADHD symptoms well based on the EEG Vigilance model, and these ADHD patients responds well to stimulant medication. In depression this subtype might be unresponsive to antidepressant treatments, and some studies suggest these depressive patients might respond better to stimulant medication. Further research should investigate whether sleep problems underlie this impaired vigilance subgroup, thereby perhaps providing a route to more specific treatments for this subgroup. Finally, a slow individual alpha peak frequency is an endophenotype associated with treatment resistance in ADHD and depression. Future studies should incorporate this endophenotype in clinical trials to investigate further the efficacy of new treatments in this substantial subgroup of patients

Arns, Martijn

Olbrich, Sebastian

Maastricht University Research Portal

Personalized medicine in ADHD and depression: Use of pharmaco-EEG

NARCIS 

This chapter summarises recent developments on personalised medicine in psychiatry with a focus on ADHD and depression and their associated biomarkers and phenotypes. Several neurophysiological subtypes in ADHD and depression and their relation to treatment outcome are reviewed. The first important subgroup consists of the 'impaired vigilance' subgroup with often-reported excess frontal theta or alpha activity. This EEG subtype explains ADHD symptoms well based on the EEG Vigilance model, and these ADHD patients responds well to stimulant medication. In depression this subtype might be unresponsive to antidepressant treatments, and some studies suggest these depressive patients might respond better to stimulant medication. Further research should investigate whether sleep problems underlie this impaired vigilance subgroup, thereby perhaps providing a route to more specific treatments for this subgroup. Finally, a slow individual alpha peak frequency is an endophenotype associated with treatment resistance in ADHD and depression. Future studies should incorporate this endophenotype in clinical trials to investigate further the efficacy of new treatments in this substantial subgroup of patients

van de Velde, Didier

Schipholt, Lars Lutje

Veeneman, Wijnand

Sydney eScholarship